Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Feb;59(2):211-5.
doi: 10.1136/jcp.2004.025452.

Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease

M Libra  1 , S S Signorelli, Y Bevelacqua, P M Navolanic, V Bevelacqua, J Polesel, R Talamini, F Stivala, M C Mazzarino, G Malaponte
Affiliations

Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease

M Libra et al. J Clin Pathol. 2006 Feb.

Abstract

Aims: To determine whether the G(-174)C interleukin 6 (IL-6) polymorphism influences the development of peripheral arterial disease (PAD) in individuals with type 2 diabetes. This was investigated by comparing the distribution of G(-174)C genotypes between patients with type 2 diabetes and PAD (PAD+) and those with type 2 diabetes but without PAD (PAD-). Plasma concentrations of IL-6, fibrinogen, C reactive protein (CRP), and vascular endothelial growth factor (VEGF) were also compared in PAD+ and PAD- patients.

Methods: Blood samples were collected from 146 PAD+ and 144 PAD- patients. SfaNI was used to determine the G(-174)C genotype. Plasma concentrations of IL-6, fibrinogen, CRP, and VEGF were measured by an enzyme linked immunosorbent assay.

Results: The GG genotype was more common in PAD+ patients than in PAD- patients. PAD+ patients also had increased mean plasma concentrations of IL-6, fibrinogen, CRP, and VEGF compared with PAD- patients. Mean plasma concentrations of IL-6, fibrinogen, and CRP in both PAD+ and PAD- patients were higher in those with the GG genotype than in those with the GC or CC genotypes. In contrast, mean plasma concentrations of VEGF in PAD+ and PAD- patients were not significantly different between those with different G(-174)C genotypes.

Conclusions: These results support a model in which the GG genotype promotes PAD development among individuals with type 2 diabetes by inducing increased release of IL-6. Higher concentrations of IL-6 among those with the GG genotype is associated with increased plasma concentrations of fibrinogen and CRP.

PubMed Disclaimer

References

    1. Al‐Delaimy W K, Merchant A T, Rimm E B.et al Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 2004116236–240. - PubMed
    1. Manaviat M R, Afkhami M, Shoja M R. Retinopathy and microalbuminuria in type II diabetic patients. BMC Ophthalmol 200449 - PMC - PubMed
    1. Meyer C, Milat F, McGrath B P.et al Vascular dysfunction and autonomic neuropathy in type 2 diabetes. Diabet Med 200421746–751. - PubMed
    1. Brevetti G, Silvestro A, Di Giacomo S.et al Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 200338374–379. - PubMed
    1. Dalmon J, Laurent M, Courtois G. The human β fibrinogen promoter contains a hepatocyte nuclear factor 1‐dependent interleukin‐6‐responsive element. Mol Cell Biol 1993131183–1193. - PMC - PubMed

Publication types